EDEM2

Across TCGA pan-cancer cohorts, EDEM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EDEM2 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EDEM2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EDEM2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where EDEM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.884	0.517	.010	17	view →
CCRCC	OS	Median	II,III,IV	1.000	0.641	.013	4	view →
HNSC	OS	Median	II,III,IV	0.940	0.994	.033	4	view →
LSCC	OS	Median	III,IV	0.996	0.680	.021	3	view →
GBM	OS	Quartile	All	0.263	0.696	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EDEM2–LUAD (DFS)

Open the LUAD breakdown →